$AIMD
Ainos, Inc. Stock $aimd

$aimd Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000165495423006377 Filed on May 12, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q1
Revenue	$28.56K	$49.16K	$87.20K
YoY Change	-95.51%	-43.62%
Cost Of Revenue	$55.82K	$100.8K	$41.08K
YoY Change	-82.5%	145.5%	3188.87%
Gross Profit	-$27.26K	-$51.68K	$46.12K
YoY Change	-108.58%	-212.06%	5189.22%
Gross Profit Margin	-95.47%	-105.13%	52.89%
Selling, General & Admin	$618.1K	$762.5K	$551.7K
YoY Change	-1.43%	38.2%	5.5%
% of Gross Profit			1196.24%
Research & Development	$1.671M	$1.699M	$1.577M
YoY Change	2.22%	7.7%
% of Gross Profit			3420.18%
Depreciation & Amortization	$1.219M	$1.205M	$1.169M
YoY Change	0.71%	3.07%
% of Gross Profit			2534.08%
Operating Expenses	$2.289M	$2.461M	$2.129M
YoY Change	1.21%	15.6%	307.12%
Operating Profit	-$2.317M	-$2.513M	-$2.083M
YoY Change	19.15%	20.64%	298.97%
Interest Expense	-$33.13K	$3.810K	$15.88K
YoY Change	-1069.53%	-76.01%	-258.83%
% of Operating Profit
Other Income/Expense, Net	$7.180K	$1.830K	$146.00
YoY Change	-20.75%	1153.42%
Pretax Income	-$2.350M	-$2.520M	-$2.100M
YoY Change	20.25%	20.03%	296.21%
Income Tax	$0.00
% Of Pretax Income
Net Earnings	-$2.350M	-$2.520M	-$2.100M
YoY Change	20.25%	20.03%	293.23%
Net Earnings / Revenue	-8228.78%	-5126.67%	-2408.14%
Basic Earnings Per Share	-$0.58	-$0.63
Diluted Earnings Per Share	-$0.12	-$0.13	-$218.2K
COMMON SHARES
Basic Shares Outstanding	20.04M shares	20.01M shares
Diluted Shares Outstanding	4.019M shares	4.002M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q1
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.361M	$1.146M	$1.871M
YoY Change	-22.4%	-38.75%	18613.5%
Cash & Equivalents	$1.361M	$1.146M	$1.871M
Short-Term Investments
Other Short-Term Assets	$241.2K	$303.3K	$813.9K
YoY Change	-81.07%	-62.73%	2613.03%
Inventory	$528.1K	$572.4K	$337.8K
Prepaid Expenses
Receivables	$9.385K	$111.3K
Other Receivables	$0.00	$1.500M
Total Short-Term Assets	$2.140M	$3.633M	$3.023M
YoY Change	-42.15%	20.18%	7457.65%
LONG-TERM ASSETS
Property, Plant & Equipment	$1.269M	$1.315M	$1.420M
YoY Change	-15.55%	-7.39%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$73.17K	$68.82K	$79.60K
YoY Change	-41.32%	-13.55%
Total Long-Term Assets	$31.91M	$33.08M	$37.71M
YoY Change	-13.09%	-12.3%	20851.78%
TOTAL ASSETS
Total Short-Term Assets	$2.140M	$3.633M	$3.023M
Total Long-Term Assets	$31.91M	$33.08M	$37.71M
Total Assets	$34.05M	$36.71M	$40.74M
YoY Change	-15.75%	-9.89%	18416.48%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable			$109.1K
YoY Change
Accrued Expenses	$429.5K	$806.0K	$1.340M
YoY Change	-83.47%	-39.83%	282.74%
Deferred Revenue
YoY Change
Short-Term Debt	$684.0K	$684.0K	$1.013M
YoY Change	-32.51%	-32.51%	322.25%
Long-Term Debt Due	$0.00	$376.5K	$3.377M
YoY Change	-100.0%	-88.85%	267.01%
Total Short-Term Liabilities	$1.114M	$1.867M	$5.730M
YoY Change	-84.07%	-67.42%	281.97%
LONG-TERM LIABILITIES
Long-Term Debt	$2.500M	$2.500M	$26.90M
YoY Change	-90.88%	-90.71%
Other Long-Term Liabilities	$37.56K	$3.280K	$24.15K
YoY Change	105.03%	-86.42%
Total Long-Term Liabilities	$37.56K	$2.503M	$26.92M
YoY Change	-99.86%	-90.7%
TOTAL LIABILITIES
Total Short-Term Liabilities	$1.114M	$1.867M	$5.730M
Total Long-Term Liabilities	$37.56K	$2.503M	$26.92M
Total Liabilities	$3.651M	$4.370M	$32.65M
YoY Change	-89.39%	-86.62%	2076.91%
SHAREHOLDERS EQUITY
Retained Earnings	-$28.99M	-$26.64M	-$12.21M
YoY Change	104.66%	118.17%
Common Stock	$202.9K	$200.1K
YoY Change	-85.94%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$30.40M	$32.34M	-$8.083M
YoY Change
Total Liabilities & Shareholders Equity	$34.05M	$36.71M	$40.74M
YoY Change	-15.75%	-9.89%	18416.48%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q1
OPERATING ACTIVITIES
Net Income	-$2.350M	-$2.520M	-$2.100M
YoY Change	20.25%	20.03%	293.23%
Depreciation, Depletion And Amortization	$1.219M	$1.205M	$1.169M
YoY Change	0.71%	3.07%
Cash From Operating Activities	-$1.151M	-$1.427M	-$1.390M
YoY Change	402.06%	2.7%	556.42%
INVESTING ACTIVITIES
Capital Expenditures	-$920.00	$72.18K	$135.9K
YoY Change	-99.78%	-46.88%
Acquisitions
YoY Change
Other Investing Activities		-$300.00	-$135.9K
YoY Change		-99.78%
Cash From Investing Activities	$1.220K	-$72.48K	-$135.9K
YoY Change	-100.42%	-46.66%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	1.391M	$795.2K	$1.645M
YoY Change	155.19%	-51.66%	727.12%
NET CHANGE
Cash From Operating Activities	-1.151M	-$1.427M	-$1.390M
Cash From Investing Activities	1.220K	-$72.48K	-$135.9K
Cash From Financing Activities	1.391M	$795.2K	$1.645M
Net Change In Cash	241.0K	-$707.2K	$119.1K
YoY Change	789.84%	-693.83%	-1025.52%
FREE CASH FLOW
Cash From Operating Activities	-$1.151M	-$1.427M	-$1.390M
Capital Expenditures	-$920.00	$72.18K	$135.9K
Free Cash Flow	-$1.150M	-$1.500M	-$1.526M
YoY Change	-688.89%	-1.72%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20011602	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	200116	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	200116	usd
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	-58965981	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	-58745149	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-26636081	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-24115606	usd
CY2023Q1	aimd	Translation Adjustment Liability TranslationAdjustmentLiability	191592	usd
CY2022Q4	aimd	Translation Adjustment Liability TranslationAdjustmentLiability	201653	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32338424	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34628006	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	36708243	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	37109014	usd
CY2023Q1	us-gaap	Revenues Revenues	49164	usd
CY2022Q1	us-gaap	Revenues Revenues	87200	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	100848	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	41078	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	-51684	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	46122	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1698883	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1577454	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	762465	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	551730	usd
CY2023Q1	us-gaap	Operating Expenses OperatingExpenses	2461348	usd
CY2022Q1	us-gaap	Operating Expenses OperatingExpenses	2129184	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2513032	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-2083062	usd
CY2023Q1	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-9273	usd
CY2022Q1	us-gaap	Interest Revenue Expense Net InterestRevenueExpenseNet	-16687	usd
CY2023Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	1830	usd
CY2022Q1	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-146	usd
CY2023Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-7443	usd
CY2022Q1	us-gaap	Interest Income Expense Nonoperating Net InterestIncomeExpenseNonoperatingNet	-16833	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2520475	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2099895	usd
CY2023Q1	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.13
CY2022Q1	aimd	Earnings Per Share Basic And Diluted1 EarningsPerShareBasicAndDiluted1	-0.22
CY2023Q1	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	20011602	shares
CY2022Q1	aimd	Weighted Average Number Of Share Outstanding Basic And Diluted1 WeightedAverageNumberOfShareOutstandingBasicAndDiluted1	9625133	shares
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2520475	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2099895	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	10061	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-58059	usd
CY2023Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2510414	usd
CY2022Q1	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2157954	usd
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001014763
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.01
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	300000000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	20011602	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20011602	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	20011602	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0
CY2022	aimd	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term22 A SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm22A	P8Y6M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Grant Date Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGrantDateIntrinsicValue	0
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	0	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	34628006	usd
CY2023Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	220832	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	-2520475	usd
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	aimd	Translation Adjustment TranslationAdjustment	-10061	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	32338424	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	10197107	usd
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2022Q1	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	43443	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2099895	usd
CY2022Q1	aimd	Translation Adjustment TranslationAdjustment	58059	usd
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	-8082596	usd
CY2023Q1	us-gaap	Profit Loss ProfitLoss	2520475	usd
CY2022Q1	us-gaap	Profit Loss ProfitLoss	2099895	usd
CY2023Q1	dei	Entity File Number EntityFileNumber	0-20791
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageIntrinsicValue	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	aimd	Aggregate Intrinsic Value Exercisable AggregateIntrinsicValueExercisable	0	shares
CY2022Q4	aimd	Aggregate Intrinsic Value Exercisable AggregateIntrinsicValueExercisable	0	shares
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	AINOS, INC.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	TX
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	75-1974352
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	8880 Rio San Diego Drive
CY2023Q1	dei	Entity Address Address Line2 EntityAddressAddressLine2	Ste. 800
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92108
CY2023Q1	dei	City Area Code CityAreaCode	858
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	869-2986
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	20040934	shares
CY2023Q1	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1146132	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1853362	usd
CY2023Q1	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	111283	usd
CY2022Q4	us-gaap	Accounts Receivable Related Parties AccountsReceivableRelatedParties	201546	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	572390	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	595222	usd
CY2023Q1	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	1500000	usd
CY2022Q4	us-gaap	Notes Receivable Related Parties NotesReceivableRelatedParties	0	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	303318	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	195787	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	3633123	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	2845917	usd
CY2023Q1	aimd	Intangible Assets Non Current IntangibleAssetsNonCurrent	31691698	usd
CY2022Q4	aimd	Intangible Assets Non Current IntangibleAssetsNonCurrent	32806738	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1314605	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1375676	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	68817	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	80683	usd
CY2023Q1	us-gaap	Assets Assets	36708243	usd
CY2022Q4	us-gaap	Assets Assets	37109014	usd
CY2023Q1	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	376526	usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	376526	usd
CY2023Q1	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	684000	usd
CY2022Q4	us-gaap	Notes Payable Related Parties Classified Current NotesPayableRelatedPartiesClassifiedCurrent	884000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	806017	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1212386	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	1866543	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	2472912	usd
CY2023Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	2500000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	0	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	3276	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	8096	usd
CY2023Q1	us-gaap	Liabilities Liabilities	4369819	usd
CY2022Q4	us-gaap	Liabilities Liabilities	2481008	usd
CY2023Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1204609	usd
CY2022Q1	us-gaap	Depreciation And Amortization DepreciationAndAmortization	1168773	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	42826	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	220832	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	43443	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	90263	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	0	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-19948	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-337805	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-107531	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-297707	usd
CY2023Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	-338003	usd
CY2022Q1	us-gaap	Increase Decrease In Other Current Liabilities IncreaseDecreaseInOtherCurrentLiabilities	133302	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1427427	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1389889	usd
CY2023Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	72184	usd
CY2022Q1	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	135899	usd
CY2023Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	-299	usd
CY2022Q1	us-gaap	Increase Decrease In Deposit Other Assets IncreaseDecreaseInDepositOtherAssets	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-72483	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-135899	usd
CY2023Q1	aimd	Payments Of Lease Liabilities PaymentsOfLeaseLiabilities	-4802	usd
CY2022Q1	aimd	Payments Of Lease Liabilities PaymentsOfLeaseLiabilities	-5116	usd
CY2023Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	1000000	usd
CY2022Q1	us-gaap	Proceeds From Secured Notes Payable ProceedsFromSecuredNotesPayable	850000	usd
CY2023Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	0	usd
CY2022Q1	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	800000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	200000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	795198	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1644884	usd
CY2023Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	2518	usd
CY2022Q1	us-gaap	Foreign Currency Transaction Gain Before Tax ForeignCurrencyTransactionGainBeforeTax	754	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-707230	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	119850	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1853362	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1751499	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1146132	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1871349	usd
CY2023Q1	aimd	Issuance Of Convertible Notes For Payables Related Party IssuanceOfConvertibleNotesForPayablesRelatedParty	0	usd
CY2022Q1	aimd	Issuance Of Convertible Notes For Payables Related Party IssuanceOfConvertibleNotesForPayablesRelatedParty	26000000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	1500000	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Notes Receivable GainLossOnSaleOfNotesReceivable	50000	usd
CY2023Q1	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	0	usd
CY2022Q1	us-gaap	Increase Decrease In Payables To Customers IncreaseDecreaseInPayablesToCustomers	202002	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	595222	usd
CY2023Q1	aimd	Aggregate Public Offering AggregatePublicOffering	780000	shares
CY2023Q1	us-gaap	Share Price SharePrice	4.25
CY2023Q1	aimd	Exercise Price Of Share ExercisePriceOfShare	4.25
CY2023Q1	aimd	Financial Conditionpolicytextblock FinancialConditionpolicytextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">These accompanying unaudited financial statements have been prepared in accordance with GAAP, on a going concern basis, which contemplates the realization of assets and the satisfaction of liabilities and commitments in the normal course of business. At March 31, 2023 and December 31, 2022, we had available cash and cash equivalents of $1,146,132 and $1,853,362, respectively. We anticipate business revenues and potential financial support from outside sources to fund our operations over the next twelve months. The Company has generated revenues from sales of COVID-19 antigen test kits since the second quarter of 2021. However, due to uncertainties surrounding the progression of COVID-19 infection, there can be no assurance that we can continue grow the COVID-19 test business. Our ability to generate product revenue sufficient to achieve profitability will depend on further successful development and commercialization of one or more of our current or future product candidates and programs. We anticipate our POCT and VELDONA candidates to potentially generate organic cash flows to support our business operation. If we obtain marketing approval for any of our product candidates, we expect to incur significant commercialization expenses related to product manufacturing, marketing, sales and distribution, and legal and regulatory compliance. We may also incur additional expenses associated with increased headcount and product development. Furthermore, we expect to incur more general and administrative expenses associated with operating as a public company, including significant legal, accounting, investor relations and other expenses.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Until we can generate significant revenue from product sales, the Company intends to seek additional funding through equity offerings or borrowing arrangements or licensing agreements or strategic alliances to implement its business plan. Please refer to the Subsequent Events section. The issuances of additional equity securities by the Company may result in dilution in the equity interests of its current stockholders. Obtaining commercial loans may increase the Company’s liabilities and future cash commitments.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">We are unable to predict the timing or amount of unexpected expenses or when or if we will be able to increase significant revenue due to the numerous risks and uncertainties associated with product development and related legal regulatory requirements, and when we are eventually able to generate additional product sales or licensing income, those revenue may not be sufficient to become profitable. Furthermore, fundraising of emerging company is extremely challenging due to the high uncertainty of the overall economic environment at present. There can be no assurance that the revenue will be generated in time or capital will be available as necessary to meet the Company’s working capital requirements or, if the capital is available, that it will be on terms acceptable to the Company.</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">If the company is unable to generate cash inflow from operating activities in the near future, and cannot complete fundraising with sufficient amount and acceptable terms, we may be unable to continue our operations at planned levels and be forced to reduce or terminate our operations. These factors raise substantial doubt about the Company’s ability to continue as a going concern, but the accompanying unaudited financial statements do not include any adjustments relative to the recoverability and classification of asset carrying amounts or the amount and classification of liabilities.</p>
CY2022Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	1853362	usd
CY2023Q1	aimd	Inventory Textblock InventoryTextblock	<p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px 0px 0px 0in; text-align:justify;"><strong>2. </strong><strong>Inventory </strong></p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventories as of March 31, 2023 and December 31, 2022 consisted of the following:</p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;margin-left:auto;margin-right:auto;width:85%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>March 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>December 31,</strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2023</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"><strong> </strong></p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;"><strong>2022</strong></p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Raw materials</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">403,358</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:12%;vertical-align:bottom;text-align:right;">393,253</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Work in process</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">84,060</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="vertical-align:bottom;text-align:right;">111,119</td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Finished goods</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">84,972</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 1px solid;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="BORDER-BOTTOM: 1px solid;vertical-align:bottom;text-align:right;">90,850</td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Total</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">572,390</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="BORDER-BOTTOM: 3px double;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="BORDER-BOTTOM: 3px double;vertical-align:bottom;text-align:right;">595,222</td><td style="PADDING-BOTTOM: 3px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;"> </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:justify;">Inventory write-downs to estimated net realizable values were $42,780 and $ 0 for the three months ended March 31, 2023 and 2022, respectively. </p>
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	403358	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	393253	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	84060	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	111119	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	84972	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	90850	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	572390	usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	10000000	shares
CY2023Q1	aimd	Schedule Of Status Of The Company Warrants ScheduleOfStatusOfTheCompanyWarrants	<table cellpadding="0" style="border-spacing:0;text-align:left;font:10pt times new roman;width:100%"><tbody><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="14" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">March 31,</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2023</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="6" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">2022</p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px"><td><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Shares</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="hdcell" colspan="2" style="BORDER-BOTTOM: 1px solid;width:9%;vertical-align:bottom;text-align:center;"><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Weighted </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Average </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Exercise </p><p style="FONT-SIZE: 10pt; FONT-FAMILY: times new roman; MARGIN: 0px; text-align:center;">Price</p></td><td style="PADDING-BOTTOM: 1px;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants outstanding at beginning of year</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Issued</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">-</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#cceeff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Warrants outstanding at the end of quarter</p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr><tr style="height:15px;background-color:#ffffff"><td style="vertical-align:top;"><p style="font-size:10pt;font-family:times new roman;margin:0px">Exercisable at the end of quarter </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">966,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">4.26</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">30,174</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td><td style="width:1%;vertical-align:bottom;white-space: nowrap;">$</td><td class="ffcell" style="width:9%;vertical-align:bottom;text-align:right;">3.98</td><td style="width:1%;white-space: nowrap;"><p style="font-size:10pt;font-family:times new roman;margin:0px"> </p></td></tr></tbody></table>
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.70
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P9Y6M14D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.70
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P8Y6M18D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	5.70
CY2023Q1	aimd	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term22 A SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm22A	P8Y3M25D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5.70
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P8Y3M25D
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	220832	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	43443	usd
CY2023Q1	aimd	Unrecognised Stock Options And Warrants UnrecognisedStockOptionsAndWarrants	1672370	usd
CY2023Q1	us-gaap	Present Value Of Future Insurance Profits Weighted Average Amortization Period PresentValueOfFutureInsuranceProfitsWeightedAverageAmortizationPeriod	P1Y8M8D
CY2023Q1	aimd	Total Convertible And Non Convertible TotalConvertibleAndNonConvertible	1060526	usd
CY2022Q4	aimd	Total Convertible And Non Convertible TotalConvertibleAndNonConvertible	1260526	usd
CY2023Q1	us-gaap	Interest Expense InterestExpense	3810	usd
CY2022Q1	us-gaap	Interest Expense InterestExpense	15883	usd
CY2023Q1	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	35970	usd
CY2022Q4	us-gaap	Accumulated Deferred Investment Tax Credit AccumulatedDeferredInvestmentTaxCredit	35282	usd
CY2023Q1	aimd	Convertible Notes Payable Non Current ConvertibleNotesPayableNonCurrent	2500000	usd
CY2022Q4	aimd	Convertible Notes Payable Non Current ConvertibleNotesPayableNonCurrent	0	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	26000000	usd
CY2022Q1	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1400000	usd
CY2022Q3	aimd	Non Current Convertible Notes Payable NonCurrentConvertibleNotesPayable	27400000	usd
CY2023Q1	us-gaap	Common Stock Dividends Shares CommonStockDividendsShares	8058818	shares
CY2023Q1	aimd	Repurchase Agreements Interest Expense Amount1 RepurchaseAgreementsInterestExpenseAmount1	26000000	usd
CY2023Q1	aimd	Principal Amount PrincipalAmount	1500000	usd
CY2023Q1	aimd	Convertible Note Issued ConvertibleNoteIssued	500000	usd
CY2023Q1	aimd	Principal Amount PrincipalAmount	1500000	usd
CY2023Q1	aimd	Convertible Note Issued ConvertibleNoteIssued	500000	usd

Files In Submission

Name	View Source	Status
aimd-20230331_def.xml	Edgar Link	unprocessable
0001654954-23-006377-index-headers.html	Edgar Link	pending
0001654954-23-006377-index.html	Edgar Link	pending
0001654954-23-006377.txt	Edgar Link	pending
0001654954-23-006377-xbrl.zip	Edgar Link	pending
aimd-20230331.xsd	Edgar Link	pending
aimd_10q.htm	Edgar Link	pending
aimd_ex241.htm	Edgar Link	pending
aimd_ex311.htm	Edgar Link	pending
aimd_ex312.htm	Edgar Link	pending
aimd_ex321.htm	Edgar Link	pending
aimd_ex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
aimd-20230331_cal.xml	Edgar Link	unprocessable
aimd-20230331_pre.xml	Edgar Link	unprocessable
aimd-20230331_lab.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
aimd_10q_htm.xml	Edgar Link	completed
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$AIMD
Ainos, Inc. Stock $aimd

2023 Q2 Form 10-Q Financial Statement

#000165495423006377 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIMD Ainos, Inc. Stock $aimd

2023 Q2 Form 10-Q Financial Statement

#000165495423006377 Filed on May 12, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$AIMD
Ainos, Inc. Stock $aimd